SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 15,299.40 |
| Enterprise Value ($M) | 15,087.88 |
| Book Value ($M) | 344.33 |
| Book Value / Share | 0.46 |
| Price / Book | 44.43 |
| NCAV ($M) | 331.26 |
| NCAV / Share | 0.45 |
| Price / NCAV | 46.19 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.69 |
| Return on Assets (ROA) | -1.36 |
| Return on Equity (ROE) | -5.45 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.63 |
| Current Ratio | 10.63 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 370.75 |
| Assets | 383.82 |
| Liabilities | 39.49 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -211.00 |
| Net Income | -221.30 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -142.10 |
| Cash from Investing | -205.30 |
| Cash from Financing | 381.20 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Duggan Robert W | 75.20 | 216.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 4,087,722 | 11,682,854 | 34.99 | |
| 3,637,179 | 13,410,782 | 27.12 | |
| 4,934,936 | 17,697,261 | 27.89 | |
| 638,609 | 1,898,431 | 33.64 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SGMT – Sagimet Biosciences Inc. | SIGA – SIGA Technologies, Inc. |
| SKYE – Skye Bioscience, Inc. | SPRY – ARS Pharmaceuticals, Inc. |
| STRO – Sutro Biopharma, Inc. |
Financial data and stock pages provided by
Fintel.io